Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.
Raggi D, Mariani L, Giannatempo P, Lo Vullo S, Giardiello D, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Calareso G, Magni M, Di Nicola M, Verzoni E, Grassi P, Procopio G, De Braud F, Pizzocaro G, Salvioni R, Necchi A.
Raggi D, et al. Among authors: de braud f.
Urol Oncol. 2015 Jul;33(7):332.e19-24. doi: 10.1016/j.urolonc.2015.04.008. Epub 2015 May 16.
Urol Oncol. 2015.
PMID: 25985712